There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (NYSE: GMED), Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Agios Pharma (NASDAQ: AGIO) with bullish sentiments.
Globus Medical (NYSE: GMED)
In a report released today, Kyle Rose from Canaccord Genuity reiterated a Buy rating on Globus Medical (NYSE: GMED), with a price target of $37. The company’s shares opened today at $29.84.
According to TipRanks.com, Rose is a 3-star analyst with an average return of 3.0% and a 46.5% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Zeltiq Aesthetics.
Currently, the analyst consensus on Globus Medical is Moderate Buy and the average price target is $33.50, representing a 12.3% upside.
In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX)
FBR Capital analyst Edward White reiterated a Buy rating on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) yesterday. The company’s shares opened today at $14.54.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -5.1% and a 41.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, RXi Pharmaceuticals Corp, and Lion Biotechnologies Inc.
Currently, the analyst consensus on Syndax Pharmaceuticals Inc is Strong Buy and the average price target is $24.50, representing a 68.5% upside.
In a report released today, Citigroup also maintained a Buy rating on the stock with a $24 price target.
Agios Pharma (NASDAQ: AGIO)
Canaccord Genuity analyst John Newman reiterated a Buy rating on Agios Pharma (NASDAQ: AGIO) today and set a price target of $90. The company’s shares opened today at $50.02.
According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -7.4% and a 35.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.
Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $71.67, representing a 43.3% upside.
In a report issued on May 4, Oppenheimer also reiterated a Buy rating on the stock with a $75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.